ID

13167

Descrizione

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT00569010

collegamento

https://clinicaltrials.gov/show/NCT00569010

Keywords

versioni (1)
  1. 21/01/16 21/01/16 -
Titolare del copyright

CC BY-NC 3.0

Caricato su

21 gennaio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Acute Myelogenous Leukemia NCT00569010

Inglese

Eligibility Acute Myelogenous Leukemia NCT00569010

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients must have histologically confirmed acute myeloid leukemia (aml) or high risk and previously treated myelodysplastic syndrome (mds).
Descrizione

AML or MDS

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C3463824
2. patients with (1) refractory disease or (2) first relapse within 6 months of therapy or (3) 2nd or more of relapse of acute myelogenous leukemia (aml) or high risk myelodysplastic syndrome mds will be considered for the study.
Descrizione

refractory disease or relapse

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0277556
3. patients must have been off chemotherapy for 4 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease.
Descrizione

chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
4. age >=18 years. deoxyribonucleic acid (dna) methylation plays a significant role in development, and the effects of azacitidine in children are not well described.
Descrizione

age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
5. patients must have normal organ as defined: total bilirubin <2 mg, aspartate aminotransferase (ast)/alanine aminotransferase (alt) <2.5 x institutional upper limit of normal, creatinine <2 mg
Descrizione

normal organ function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0364051
UMLS CUI [3]
C0201976
6. ability to understand and the willingness to sign a written informed consent document.
Descrizione

written informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
7. women of child bearing potential must have a negative serum pregnancy test prior to azacitidine treatment.
Descrizione

pregnancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
8. women of child bearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with azacytidine.
Descrizione

contraception

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0700589
9. eastern cooperative oncology group (ecog) performance status 0-2.
Descrizione

ecog performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, unless there is evidence of rapidly progressive disease. patients may have received hydroxyurea prior to entering the study.
Descrizione

chemotherapy or radiotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
2. patients may not be receiving any other investigational agents for their leukemias.
Descrizione

investigational agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1875319
3. patients with active brain or meningeal disease should be excluded.
Descrizione

cns leukemia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1332884
4. known or suspected hypersensitivity to azacitidine or mannitol
Descrizione

hypersensitivity to azacitidine or mannitol

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0004475
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0024730
5. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
Descrizione

illness that would limit compliance with study requirements

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
6. pregnant women are excluded from this study because azacitidine is a deoxyribonucleic acid (dna) methyltransferase inhibitor which has teratogenic or abortifacient effects. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with azacitidine, breastfeeding should be discontinued if the mother is treated with azacitidine.
Descrizione

pregnancy or lactation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Ritorna all'inizio della pagina

Similar models

Eligibility Acute Myelogenous Leukemia NCT00569010

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
AML or MDS
Item
1. patients must have histologically confirmed acute myeloid leukemia (aml) or high risk and previously treated myelodysplastic syndrome (mds).
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
refractory disease or relapse
Item
2. patients with (1) refractory disease or (2) first relapse within 6 months of therapy or (3) 2nd or more of relapse of acute myelogenous leukemia (aml) or high risk myelodysplastic syndrome mds will be considered for the study.
boolean
C0277556 (UMLS CUI [1])
chemotherapy
Item
3. patients must have been off chemotherapy for 4 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease.
boolean
C0392920 (UMLS CUI [1])
age
Item
4. age >=18 years. deoxyribonucleic acid (dna) methylation plays a significant role in development, and the effects of azacitidine in children are not well described.
boolean
C0001779 (UMLS CUI [1])
normal organ function
Item
5. patients must have normal organ as defined: total bilirubin <2 mg, aspartate aminotransferase (ast)/alanine aminotransferase (alt) <2.5 x institutional upper limit of normal, creatinine <2 mg
boolean
C1278039 (UMLS CUI [1])
C0364051 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
written informed consent
Item
6. ability to understand and the willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
pregnancy
Item
7. women of child bearing potential must have a negative serum pregnancy test prior to azacitidine treatment.
boolean
C0032961 (UMLS CUI [1])
contraception
Item
8. women of child bearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with azacytidine.
boolean
C0700589 (UMLS CUI [1])
ecog performance status
Item
9. eastern cooperative oncology group (ecog) performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
chemotherapy or radiotherapy
Item
1. patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, unless there is evidence of rapidly progressive disease. patients may have received hydroxyurea prior to entering the study.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
investigational agent
Item
2. patients may not be receiving any other investigational agents for their leukemias.
boolean
C1875319 (UMLS CUI [1])
cns leukemia
Item
3. patients with active brain or meningeal disease should be excluded.
boolean
C1332884 (UMLS CUI [1])
hypersensitivity to azacitidine or mannitol
Item
4. known or suspected hypersensitivity to azacitidine or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C0004475 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
illness that would limit compliance with study requirements
Item
5. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
pregnancy or lactation
Item
6. pregnant women are excluded from this study because azacitidine is a deoxyribonucleic acid (dna) methyltransferase inhibitor which has teratogenic or abortifacient effects. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with azacitidine, breastfeeding should be discontinued if the mother is treated with azacitidine.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial